Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
PELTHOS THERAPEUTICS INC (PTHS) Stock Price & Overview
NYSEARCA:PTHS • US1711262048
Current stock price
24.93 USD
-0.16 (-0.64%)
Last:
The current stock price of PTHS is 24.93 USD. Today PTHS is down by -0.64%. In the past month the price increased by 19.42%.
PTHS Key Statistics
1-Month Range20.1 - 26.47
Current PTHS stock price positioned within its 1-month range.
- Market Cap
- 83.765M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -20.71
- Dividend Yield
- N/A
PTHS Stock Performance
Today
-0.64%
1 Week
+9.09%
1 Month
+19.42%
3 Months
+4.45%
Longer-term
6 Months -23.97%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
PTHS Stock Chart
PTHS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to PTHS.
Chartmill TA Rating
Chartmill Setup Rating
PTHS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PTHS. The financial health of PTHS is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PTHS Earnings
On March 19, 2026 PTHS reported an EPS of -2.03 and a revenue of 9.39M. The company beat EPS expectations (51.81% surprise) and beat revenue expectations (1.26% surprise).
Next Earnings DateN/A
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS Reported-$2.03
Revenue Reported9.389M
EPS Surprise 51.81%
Revenue Surprise 1.26%
PTHS Forecast & Estimates
12 analysts have analysed PTHS and the average price target is 58.29 USD. This implies a price increase of 133.8% is expected in the next year compared to the current price of 24.93.
For the next year, analysts expect an EPS growth of 48.61% and a revenue growth 266.6% for PTHS
Analysts
Analysts83.33
Price Target58.29 (133.81%)
EPS Next Y48.61%
Revenue Next Year266.6%
PTHS Financial Highlights
Over the last trailing twelve months PTHS reported a non-GAAP Earnings per Share(EPS) of -20.71.
Income Statements
Revenue(TTM)16.80M
Net Income(TTM)-23.58M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.65% | ||
| ROE | -40.48% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%36.56%
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
PTHS Ownership
Ownership
Inst Owners32.92%
Shares3.36M
Float1.46M
Ins Owners1.32%
Short Float %3.15%
Short Ratio4.94
PTHS Industry Overview
PTHS operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.6
- Average Fwd P/E
- 22.2
- Average Debt/Equity
- 2.2
PTHS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.92 | 360.632B | ||
| AMGN | AMGEN INC | 15.22 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.84 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.08 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.77 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.38 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.57 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.57 | 25.03B | ||
| INCY | INCYTE CORP | 10.74 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PTHS
Company Profile
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The firm also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Company Info
IPO: 2024-02-16
PELTHOS THERAPEUTICS INC
4020 Stirrup Creek Drive, Suite 110
Durham NORTH CAROLINA US
Employees: 92
Phone: 19199082422
PELTHOS THERAPEUTICS INC / PTHS FAQ
What does PELTHOS THERAPEUTICS INC do?
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The firm also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
What is the stock price of PELTHOS THERAPEUTICS INC today?
The current stock price of PTHS is 24.93 USD. The price decreased by -0.64% in the last trading session.
What is the dividend status of PELTHOS THERAPEUTICS INC?
PTHS does not pay a dividend.
What is the ChartMill rating of PELTHOS THERAPEUTICS INC stock?
PTHS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of PTHS stock?
PELTHOS THERAPEUTICS INC (PTHS) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for PELTHOS THERAPEUTICS INC?
PELTHOS THERAPEUTICS INC (PTHS) has a market capitalization of 83.76M USD. This makes PTHS a Micro Cap stock.
Can you provide the short interest for PTHS stock?
The outstanding short interest for PELTHOS THERAPEUTICS INC (PTHS) is 3.15% of its float.